Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iovance Biotherapeutics, Inc.    IOVA

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2020 03/24/2020 03/25/2020 03/26/2020 03/27/2020 Date
23.81(c) 32.14(c) 30.36(c) 31.96(c) 32.16(c) Last
1 463 648 5 601 521 3 313 583 1 489 977 1 879 681 Volume
+4.57% +34.99% -5.54% +5.27% +0.63% Change
More quotes
Financials (USD)
Sales 2020 -
EBIT 2020 -277 M
Net income 2020 -274 M
Finance 2020 330 M
Yield 2020 -
Sales 2021 58,2 M
EBIT 2021 -303 M
Net income 2021 -302 M
Finance 2021 93,0 M
Yield 2021 -
P/E ratio 2020 -15,4x
P/E ratio 2021 -14,8x
EV / Sales2020 -
EV / Sales2021 68,3x
Capitalization 4 068 M
More Financials
Company
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer... 
Sector
Biotechnology & Medical Research
Calendar
04/16 | 02:15pmPresentation
More about the company
Surperformance© ratings of Iovance Biotherapeutics, I
Trading Rating : Investor Rating : -
More Ratings
Latest news on IOVANCE BIOTHERAPEUTICS, I
03/02Iovance Biotherapeutics to Present at Upcoming Conferences
GL
02/26WALL STREET STOCK EXCHANGE : Salesforce’s CEO resigns, Walt Disney’s Robert Iger..
02/25IOVANCE BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Cond..
AQ
02/25IOVANCE BIOTHERAPEUTICS : 4Q Earnings Snapshot
AQ
02/25IOVANCE BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, F..
AQ
02/25Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial R..
GL
02/19Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial R..
GL
02/12Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
GL
01/15IOVANCE BIOTHERAPEUTICS : Clinigen signs agreement with iovance biotherapeutics ..
AQ
01/15Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Coh..
GL
01/13IOVANCE BIOTHERAPEUTICS : Shares Down 10% After Licensing Drug From Novartis
DJ
01/12Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel ..
GL
01/12Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and..
GL
2019Iovance Biotherapeutics to Present at Upcoming Investor Conferences in Decemb..
GL
2019Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients ..
GL
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, I
02/26EN DIRECT DES MARCHES : Thales, Danone, Peugeot, Europcar, Ingenico, Disney, ..
02/26STOCK MARKET PARIS : Rester sur le marché ou le quitter, telle est la question
01/13EN DIRECT DES MARCHES : Renault, Peugeot, Casino, Vivendi, Bourbon, Gaumont, ..
01/13STOCK MARKET PARIS : L'accord commercial Chine / Etats-Unis se profile
More news
Chart IOVANCE BIOTHERAPEUTICS, I
Duration : Period :
Iovance Biotherapeutics, I Technical Analysis Chart | IOVA | US4622601007 | MarketScreener
Technical analysis trends IOVANCE BIOTHERAPEUTICS, I
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 40,00  $
Last Close Price 32,16  $
Spread / Highest target 86,6%
Spread / Average Target 24,4%
Spread / Lowest Target 8,83%
EPS Revisions
Managers
NameTitle
Maria Fardis President, Chief Executive Officer & Director
Iain D. Dukes Chairman
Timothy E. Morris Chief Financial Officer & Treasurer
Friedrich Graf Finckenstein Chief Medical Officer
Merrill A. McPeak Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IOVANCE BIOTHERAPEUTICS, INC.16.19%4 068
EXACT SCIENCES CORPORATION-37.53%8 567
GUARDANT HEALTH, INC.-13.25%6 398
ADAPTIVE BIOTECHNOLOGIES CORPORATION-15.17%3 206
GENSCRIPT BIOTECH CORPORATION-1.25%2 880
SEEGENE INC--.--%2 469